Cargando…

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)

SIMPLE SUMMARY: Many head-and-neck cancer patients assigned to chemoradiation cannot receive concurrent cisplatin due to impaired renal function. Carboplatin may be an alternative option. We compared the chemoradiation outcomes of 131 patients who received cisplatin vs. 45 patients who were unfit fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rades, Dirk, Zwaan, Inga, Soror, Tamer, Idel, Christian, Pries, Ralph, Bruchhage, Karl L., Hakim, Samer G., Yu, Nathan Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340068/ https://www.ncbi.nlm.nih.gov/pubmed/37444388 http://dx.doi.org/10.3390/cancers15133278

Ejemplares similares

A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
por: Rades, Dirk, et al.
Publicado: (2023)

First Results of Concurrent Chemoradiation with Two Courses of 5 × 25 mg/m(2) Cisplatin for Locally Advanced Head and Neck Cancer
por: Zwaan, Inga, et al.
Publicado: (2023)

Smoking-, Alcohol-, and Age-Related Alterations of Blood Monocyte Subsets and Circulating CD4/CD8 T Cells in Head and Neck Cancer
por: Idel, Christian, et al.
Publicado: (2022)

Salvage High-Dose-Rate Interventional Radiotherapy (Brachytherapy) Combined with Surgery for Regionally Relapsed Head and Neck Cancers
por: Soror, Tamer, et al.
Publicado: (2023)

A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)
por: Guan, Jian, et al.
Publicado: (2016)

Increased Abundances of CD16(+) Non-Classical Monocytes Accompany with Elevated Monocytic PD-L1 and CD4(+) T Cell Disturbances in Oropharyngeal Cancer
por: Idel, Christian, et al.
Publicado: (2022)

Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer – results of a randomized phase III trial (RAREST-02)
por: Rades, Dirk, et al.
Publicado: (2022)

Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas
por: Idel, Christian, et al.
Publicado: (2021)

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC
por: von Bernuth, Amelie, et al.
Publicado: (2023)

Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines
por: Wolff, Hendrik A., et al.
Publicado: (2010)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2017)

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2018)

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Katori, H, et al.
Publicado: (2004)

Plasma‑derived CD16 exosomes and peripheral blood monocytes as correlating biomarkers in head and neck cancer
por: Theodoraki, Marie-Nicole, et al.
Publicado: (2023)

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
por: Agulnik, Mark
Publicado: (2012)

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Hanemaaijer, Saskia H., et al.
Publicado: (2020)

Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)
por: Xu, Bei, et al.
Publicado: (2018)

CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer
por: Jagomast, Tobias, et al.
Publicado: (2022)

Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand
por: Tharavichitkul, Ekkasit, et al.
Publicado: (2016)

Prognostic impact of the loss of E-cadherin and de novo expression of N-cadherin at the invasive front of primary and recurrent oral squamous cell carcinoma
por: Hakim, Samer George, et al.
Publicado: (2023)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Concurrent chemoradiation with carboplatin for locally advanced cervical cancer at high-risk for developing cisplatin-induced renal dysfunction
por: Cetina, Lucely, et al.
Publicado: (2007)

Randomized trial on acute toxicities of weekly vs three‐weekly cisplatin‐based chemoradiation in head and neck cancer
por: Ameri, Ahmad, et al.
Publicado: (2021)

Immunologic “Cold” Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiation
por: Soror, Tamer, et al.
Publicado: (2023)

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
por: Möckelmann, Nikolaus, et al.
Publicado: (2016)

Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study
por: Joseph, Deepa M., et al.
Publicado: (2021)

Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population––A SEER‐based analysis from 2000 to 2016
por: Taylor, Melissa A., et al.
Publicado: (2021)

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC
por: Paulsen, Finn-Ole, et al.
Publicado: (2020)

NR2F6 as a Prognostic Biomarker in HNSCC
por: Klapper, Luise, et al.
Publicado: (2020)

TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC
por: Klapper, Luise, et al.
Publicado: (2022)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
por: Tsakonas, Georgios, et al.
Publicado: (2020)

Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Jensen, Alexandra D, et al.
Publicado: (2011)

The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN)
por: Scheckenbach, Kathrin, et al.
Publicado: (2010)

Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience
por: Jensen, Alexandra D, et al.
Publicado: (2010)

Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe
por: Singh, Prianka, et al.
Publicado: (2021)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans
por: Azar, Ibrahim, et al.
Publicado: (2022)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_76us61eauj6cm9ect1dovlnae0